TMates vs BreezeMeds: Price, meds, and clinician access compared

Quick verdict: TMates vs BreezeMeds shows TMates as a flat-rate, clinician-access focused semaglutide program at $199/month, while BreezeMeds lists multiple GLP-1 options with starting prices that vary and require clinician review for eligibility and exact cost. TMates emphasizes 24/7 U.S. doctor access and the same price at every dose; BreezeMeds highlights injectable and oral options and discreet shipping with pricing starting at $199.

Explore TMates semaglutide plan

How they differ: price transparency and pricing model

TMates uses a flat $199/month price for compounded semaglutide, described as the same price at every dose with no step-up fees. BreezeMeds shows a range of starting prices: semaglutide injection from $199/mo, tirzepatide injection from $299, and oral options from $399, plus a separate $169 figure that is not clearly tied to a specific product. TMates’ pricing is presented as a predictable monthly fee; BreezeMeds presents starting points that require confirmation of the full cost and eligibility.

Clinician access and medical oversight

TMates emphasizes 24/7 access to U.S.-based doctors across all 50 states and virtual check-ins for ongoing medical oversight. BreezeMeds notes clinician-reviewed online treatment and stresses that treatment is available only when a licensed clinician determines it is medically appropriate. The difference is TMates markets continuous physician availability, while BreezeMeds frames access as clinician review and eligibility determination for specific medications.

Get TMates doctor-supervised care

Medication types and formulation options

TMates is presented as offering clinically dosed compounded semaglutide formulated in U.S. facilities. TMates’ materials mention compounded semaglutide specifically and note no branded Ozempic, Wegovy, or Zepbound. BreezeMeds lists both injectable and oral GLP-1 options: semaglutide injection, tirzepatide injection, and oral semaglutide and tirzepatide. BreezeMeds therefore shows a broader set of delivery forms and both semaglutide and tirzepatide in listings, while TMates is focused on compounded semaglutide in the captured evidence.

Regulatory and compounding notes

Both sources include caveats about compounded medications. TMates’ evidence includes the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. BreezeMeds similarly indicates that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Both platforms require confirmation of eligibility and medical appropriateness by clinicians.

Direct comparison table

Patient experience and best-for guidance

TMates positions itself for patients who want a predictable flat-rate GLP-1 program with ongoing physician availability and U.S.-formulated compounded semaglutide. BreezeMeds is presented for people who need multiple formulation options and who will confirm eligibility, medication, total cost, renewal terms and state availability with a clinician before enrollment. BreezeMeds emphasizes discreet shipping and a broader product menu in the captured evidence.

Choose TMates if…

you want a flat $199/month semaglutide program with the same price at every dose, 24/7 access to U.S.-based doctors, and U.S.-formulated compounded semaglutide with virtual check-ins.

Start TMates enrollment

In summary, TMates vs BreezeMeds contrasts TMates’ predictable flat pricing and continuous U.S. physician access for compounded semaglutide with BreezeMeds’ broader listing of injectable and oral GLP-1 options and starting-at pricing that is subject to clinician review and confirmation. Use TMates for transparent flat-rate semaglutide care; use BreezeMeds if you need to confirm multiple medication forms, eligibility, and exact pricing with a clinician before proceeding.